• linkedin
  • Increase Font
  • Sharebar

    How number of Peyronie’s Tx cycles affects outcomes

    Findings of a retrospective review of men receiving intralesional collagenase clostridium histolyticum (CCH; Xiaflex) for Peyronie’s disease may help inform therapeutic decisions on number of cycles.

    Also from AUA 2016: Data weigh neuromodulation’s impact on QoL at 3 years

    Conducted by researchers at Tulane University School of Medicine in New Orleans, the study analyzed serial and total changes in penile curvature in 77 men, of whom 41 (53%) completed four cycles of CCH treatment (eight total injections). The findings were presented at the AUA annual meeting in San Diego.

    Overall, mean curvature decreased significantly from 58.2° at baseline to 41.0° after the last cycle of injections. Comparing men who achieved a ≥20° change from baseline to those with less curvature reduction based on a number of variables showed the two groups differed significantly only in the amount of curvature reduction achieved after the first treatment cycle (–16.2° vs. –5.9°, respectively; p<.001).

    Have you read: AS success rate strong in appropriate PCa patients

    Analysis of change in penile curvature after each injection cycle was done using a repeated measures model. It showed mean curvature was reduced most dramatically after the first cycle (–12.0°), and there was continued improvement between the second and third and third and fourth sets of injections (mean reduction of –4.6° and –4.8°, respectively). However, there was essentially no significant change in penile curvature as a result of the fourth cycle, said first author James Anaissie.

    Next: “Our study indicates that urologists may counsel patients who have a strong response to the first cycle that they are likely to have a better final outcome"

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll